Department of Biology, Faculty of Sciences, Shahid Bahonar University of Kerman, Kerman, Iran.
Institute of Biochemistry and Molecular Biology II, Medical Faculty, Heinrich Heine University, Düsseldorf, Germany.
Bioprocess Biosyst Eng. 2022 Nov;45(11):1781-1797. doi: 10.1007/s00449-022-02785-x. Epub 2022 Sep 20.
Herein, we designed a DNA framework-based intelligent nanorobot using toehold-mediated strand displacement reaction-based molecular programming and logic gate operation for the selective and synchronous detection of miR21 and miR125b, which are known as significant cancer biomarkers. Moreover, to investigate the applicability of our design, DNA nanorobots were implemented as capping agents onto the pores of MSNs. These agents can develop a logic-responsive hybrid nanostructure capable of specific drug release in the presence of both targets. The prosperous synthesis steps were verified by FTIR, XRD, BET, UV-visible, FESEM-EDX mapping, and HRTEM analyses. Finally, the proper release of the drug in the presence of both target microRNAs was studied. This Hybrid DNA Nanostructure was designed with the possibility to respond to any target oligonucleotides with 22 nucleotides length.
在这里,我们设计了一种基于 DNA 框架的智能纳米机器人,利用基于引发链置换反应的分子编程和逻辑门操作,用于选择性和同步检测 miR21 和 miR125b,这两种 miRNA 都被认为是重要的癌症生物标志物。此外,为了研究我们设计的适用性,将 DNA 纳米机器人用作介孔硅纳米粒子(MSNs)孔道的封端剂。这些试剂可以形成一种逻辑响应的混合纳米结构,在存在两个靶标的情况下能够实现特定的药物释放。通过傅里叶变换红外光谱(FTIR)、X 射线衍射(XRD)、比表面积和孔隙度分析(BET)、紫外-可见光谱(UV-visible)、场发射扫描电子显微镜-能量色散 X 射线谱(FESEM-EDX mapping)和高分辨率透射电子显微镜(HRTEM)分析验证了合成步骤的合理性。最后,研究了在存在两个靶标 microRNA 的情况下药物的适当释放情况。这种混合 DNA 纳米结构具有响应任何长度为 22 个核苷酸的目标寡核苷酸的可能性。